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Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally
nephrectomized rats. In the past, there has been considerable concern
that treatment with active vitamin D might accelerate progression inde-
pendent of hypercalcemia and hypercalcuria. Nevertheless, 1,25(OH)2D3
has known antiproliferative properties and has also been shown to inhibit
renal growth. Since glomerular growth is a permissive factor for the
development of glomerulosclerosis, we reasoned that 1,25(OH)2D3 might
even attenuate progression. To test this working hypothesis we performed
two experiments of 8 and 16 weeks duration, respectively, to compare
subtotally nephrectomized (SNX) rats treated with ethanol and SNX
treated with 1,25(OH)2D3. Control animals were sham operated and
pair-fed with SNX animals. 1,25(OH)2D3 (3 ng/100 g body wt/day) was
administered by osmotic minipump. 1,25(OH)2D3 had no significant effect
on systolic blood pressure and only a transient effect on weight gain. SNX
reduced the number of glomeruli (left kidney) from an average of 3.3 3
104 to 1.2 3 104 per kidney. Mean glomerular volume was 3.87 6 0.71 3
106 mm3 in sham operated animals and significantly (P , 0.05) higher
(10.1 6 1.75 3 106 mm3) in untreated animals 16 weeks after SNX.
Glomerular volume was significantly (P , 0.05) less in 1,25(OH)2D3
treated SNX [10.1 6 1.75 in ethanol vs. 7.04 6 1.78 in 1,25(OH)2D3
treated SNX]. In parallel, there was significantly (P , 0.01) less glomer-
ulosclerosis [glomerulosclerosis index 1.16 6 0.14 in the ethanol treated
SNX vs. 0.80 6 0.16 in SNX treated with 1,25(OH)2D3] in the eight week
experiment. Albuminuria was significantly (P , 0.01) lower in
1,25(OH)2D3 treated than in ethanol treated SNX (mean 0.785 mg/24 hr,
range 0.43 to 1.80, vs. 3.75 mg/24 hr, 1.29 to 14.2). The morphological data
were directionally analogous in a second 16 week experiment. Only slight
changes of the vascular sclerosis index and tubulointerstitial index were
seen in SNX and were not affected by 1,25(OH)2D3 further. To prove that
the effect of 1,25(OH)2D3 was independent of PTH, parathyreoidecto-
mized SNX rats without or with 1,25(OH)2D3 treatment were examined
seven days post-SNX. PCNA staining showed suppression of cell prolif-
eration. Furthermore, in situ hybridization for transforming growth fac-
tor-B (TGF-b) showed less vascular and tubular expression in
1,25(OH)2D3 treated rats. We conclude that 1,25(OH)2D3 has antiprolif-
erative actions during the compensatory growth of nephrons in response
to subtotal nephrectomy. These effects are independent of PTH. The data
document that 1,25(OH)2D3 reduces renal cell proliferation and glomer-
ular growth as well as glomerulosclerosis and albuminuria as indicators of
progressive glomerular damage.
After treatment with high doses of vitamin D3 was introduced
for uremic patients with disturbed calcium metabolism [1], more
rapid progression of renal failure was noted in many patients. This
was attributed to vitamin D toxicity as a result of hypercalcemia.
While Christiansen, Rodbro and Christiansen [2] proposed that
active vitamin D metabolites were nephrotoxic independently of
hypercalcuria and hypercalcemia, this hypothesis has not been
confirmed in several prospective controlled trials [3–7].
In view of such historical concerns about the potential intrinsic
nephrotoxicity of active vitamin D, it is paradoxical that some
recent experimental findings would be consistent even with a
nephroprotective effect of 1,25(OH)2D3. In numerous cell sys-
tems, such as, keratinocytes [8], chondrocytes [9], colonic carci-
noma cells [10], lymphoma cells [11] or monocytoid cells U 937
[12] 1,25(OH)2D3 was shown to inhibit cell proliferation and to
promote cell differentiation. Apparently this also applies to the
kidney. In a renal cell carcinoma line, Nagakura et al [13] showed
a dose-dependent inhibition of proliferation by 1,25(OH)2D3.
Examining renal compensatory growth after uninephrectomy, in
vivo experiments of Matthias et al [14] documented that
1,25(OH)2D3 reduced renal weight, renal protein content, renal
DNA content and the number of mitoses. These effects were
independent of PTH secretion. Finally, at least in vitro, both in
human mesangial cells [15] and in a proximal tubular cell line [16]
1,25(OH)2D3 diminished radiothymidin incorporation, cell counts
and TGF-b secretion into the supernatant [17]. Such antiprolif-
erative actions of 1,25(OH)2D3 may be related to the recently
described activation of the Cdk inhibitor p21 by the active vitamin
D metabolite [18].
It is commonly assumed that glomerular growth is a factor
that favors progression of glomerulosclerosis [19]. This hypoth-
esis has provided the rationale to examine whether
1,25(OH)2D3 exerted a beneficial effect in the renal ablation
model. To this end we compared solvent treated and
1,25(OH)2D3 treated subtotally nephrectomized rats. We mea-
sured glomerular morphology by stereological techniques, as-
sessed cell proliferation using the PCNA technique, analyzed
expression of the sclerosis promoting cytokine TGF-b using
non-radioactive in situ hybridization, and assessed urinary
albumin excretion using immune detection. To exclude the
possibility that the effect of 1,25(OH)2D3 was mediated via
suppression of PTH, treatment with 1,25(OH)2D3 was also
assessed in parathyroidectomized SNX rats.
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METHODS
Animals
Male 160 to 180 g Sprague Dawley rats (SD) were housed in single
cages at constant room temperature (20°C) and humidity (75%)
under a controlled light/dark cycle. The rats were fed a diet
containing a 20% protein, 0.9% calcium/100 g and 600 IE vitamin
D3 per kg. The animals had free access to drinking water.
Surgery
After a three-day adaptation period, the animals were randomly
allotted to sham operation or subtotal nephrectomy (SNX). For
subtotal nephrectomy the right kidney was removed in a first
session. Eight days after the first operation 75% of cortical tissue
by weight was removed surgically under anesthesia with Ketanest
(100 mg/kg body wt) and Rompun (2 mg/kg body wt). In sham
operated animals, both kidneys were decapsulated in two sessions.
For parathyroidectomy (PTX) the parathyroids were removed
using microsurgical techniques.
Protocol
Sham operated and subtotally nephrectomized (SNX) rats were
pair-fed, that is, control animals received the amount of food
consumed by the matched SNX animals on the preceeding day.
The animals were given 1,25(OH)2D3 or ethanol by osmotic
minipump. The dose of 1,25(OH)2D3 was 3 ng/100 g body wt/day.
A pilot study showed that in non-SNX rats treated with this dose,
serum calcium (SCa) did not exceed 2.51 mmol/liter. Administra-
tion was via a Savo Company minipump model 2 ml 4 (Kisslegg,
Allga¨u, Germany) at an hourly delivery rate of 2.5 ml.
Two main experiments were carried out. In the first experiment,
animals were studied for eight weeks comparing (i) sham-oper-
ated solvent treated, (ii) sham-operated 1,25(OH)2D3 treated,
(iii) SNX ethanol treated, and (iv) SNX 1,25(OH)2D3 treated rats.
In each group, there were at least 8 to 12 animals. In the second
experiment with the same protocol, animals were studied for 16
weeks.
In the above two experiments, ethanol treated sham-operated
animals were pair-fed with ethanol treated SNX; the
1,25(OH)2D3 treated sham-operated animals were pair-fed with
1,25(OH)2D3 treated SNX. In these two series the kidneys were
examined by morphological techniques. Since food intake had
been somewhat lower in 1,25(OH)2D3 treated animals, in a repeat
of the eight week experiment the SNX ethanol treated animals
were pair-fed with SNX 1,25(OH)2D3 treated animals to exclude
a lower food intake in 1,25(OH)2D3 treated animals as a con-
founding factor. All other conditions were kept identical. In this
latter experiment parameters of calcium metabolism and urinary
albumin excretion were measured.
In ancillary studies animals were treated for immunhistochemi-
cal and molecular biological examination. The experimental de-
tails are described below.
Measurements
Body weight and serum calcium were measured at regular inter-
vals.
At the end of the experiment, blood samples were taken for
routine chemistry (Autoanalyzer, Fa. Hitachi, Japan). Systolic
blood pressure was measured by tail cuff plethysmography. The
experiment was terminated by retrograde perfusion fixation via
the abdominal aorta as described in detail elsewhere [20].
1,25(OH)2D3 was measured immunoradiometrically as described
elsewere [21]. Urinary albumin was measured using the micro-
plate technique described by Magnotti et al [22], modified by
using a rabbit anti-rat albumin peroxydase conjugate.
Tissue preparation
The kidneys were taken out, weighed and then dissected in a plane
perpendicular to the interpolar axis, yielding slices of 1 mm width.
Ten small pieces of each kidney were selected by area weighted
sampling [20] for embedding in Epon-Araldite. The remaining
tissue slices were embedded in paraffin; 4 mm sections were taken
and stained with hematoxylin/eosin (HE) and PAS. Subsequently,
the kidneys were investigated by means of morphometry and
stereology [23, 24].
For immunohistological investigations (PCNA) one half of the
kidney was fixed in 8% buffered formaldehyde. For in situ
hybridization, the other half of the kidney was snap-frozen in
liquid nitrogen-cooled isopentane. Cryostat sections 12 mm in
thickness were thaw-mounted on silane-coated slides and fixed for
five minutes in 3% paraformaldehyde/phosphate buffered saline
(PBS), pH 7.0. Deproteination was performed in 0.2 M HCl. To
reduce the nonspecific background, the sections were acetylated
for 20 minutes in 0.25% acetic acid (vol/vol) in 0.1 M triethanol-
amine, pH 8.0. After dehydration in graded alcohols, the sections
were allowed to air-dry prior to prehybridization.
Immunohistological staining
For PCNA staining an anti-PCNA antibody (Immunotech 1510
mono, Marseille, France) was used in a 1:150 dilution. The
concentration that was optimal for staining was evaluated testing
different dilution-series in a pilot study.
To avoid nonspecific reactions (cross reaction) of tissue com-
ponents with antibody, a biotin-streptavidin detection system
(biotin-streptavidin super sensitive; Fa. BioGenex, San Ramon,
CA, USA) was selected for staining the specimen. With this
system nonspecific cross reactions can be excluded. Furthermore,
a high sensitivity can be achieved even with short incubation
times. The following immunhistochemical protocol was used: 15
minutes TUF (90°C), 60 minutes primary antibody, 3 3 5 minutes
TBS pH 7.6, 30 minutes anti-PCNA antibody (Immunotech 1510
mono diluted 1:150), 3 3 5 minutes TBS, pH 7.6, 30 minutes
Label (super sensitive; Fa. BioGenex), 30 minutes Levamisole
0.2 g, and 100 ml TBS, pH 7.6, fast red substrate system (DAKO),
Mayers ha¨malaun.
In situ hybridization
Probe preparation and labeling. A 404 bp cDNA encoding
positions 1.156 to 1.559 of the rat TGF-b1 gene [25] was inserted
into the expression vector pGEM-5Zf(1) (Promega Biotech.,
Madison, WI, USA). To generate an antisense RNA probe, the
plasmid was linearized with SalI and transcribed using T7 RNA
polymerase. For preparation of the sense RNA probe, the plasmid
was linearized with NcoI and transcribed using SP6 RNA poly-
merase.
Digoxigenin-labeled RNA probes were synthesized with a DIG
RNA labeling mix (Boehringer Mannheim GmbH, Mannheim,
Germany) according to the manufacturer’s instructions. Briefly,
labeled transcripts were generated in 20 ml transcription buffer
[40 mM Tris-HCl, pH 8.0, 6 mM MgCl2, 10 mM dithiothreitol
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(DTT), 2 mM spermidine] containing 1 mg agarose gel-extracted
linearized plasmid, NTP-labeling mix (1 mM each of ATP, CTP
and GTP, 0.65 mM UTP, 0.35 mM DIG-UTP), 20 U of RNAsin
ribonuclease inhibitor and 40 U of T7 and SP6 RNA polymerase,
respectively. The reaction was stopped by digestion of the DNA
template with RNase-free DNase and the labeled transcripts were
ethanol-precipitated at 220°C overnight. Subsequently, the
probes were pelleted and resuspended in DEPC-treated water.
The probe concentration was determined in a UV-spectropho-
tometer at 260 nm. Incorporation efficiency of digoxigenin-11-d-
UTP into the probe and probe length were estimated by running
an aliquot on a denaturating formaldehyde gel, blotting it onto a
nylon membrane and comparing the size and intensity of the
colorimetric reaction from a diluted, labeled, control RNA
(Boehringer Mannheim).
In situ hybridization. The fixed sections were prehybridized for
four hours at 38°C with 50% deionized formamide, 50 mM
Tris-HCl, pH 7.6, 25 mM EDTA, pH 8.0, 0.625 mg/ml yeast tRNA,
2.5 3 Denhardt’s solution [0.05% Ficoll 400, 0.05% polyvinylpy-
rollidone, 0.05% bovine serum albumine (BSA)], and 20 mM NaCl
in a humidified chamber. Then, 120 ng labeled probe per section
in hybridization buffer (50% deionized formamide, 20 mM Tris-
HCl, pH 7.6, 0.33 M NaCl, 0.1 M DTT, 10% dextran sulfate, 0.5
mg/ml yeast tRNA, 0.1 mg/ml poly-A-RNA, 13 Denhardt’s
solution) was applied to the sections. Hybridization of the probe
with the native mRNA was allowed for 18 hours at 38°C.
Post-hybridization steps included removal of coverslips in 1 3
standard saline citrate (SSC) at 48°C, two subsequent washes in
0.5 3 SSC/50% formamide for one hour at 48°C, RNase A
treatment (10 mg/ml) in 0.5 M NaCl, 10 mM Tris-HCl, pH 8.0, 1
mM EDTAm pH 7.5 for 30 minutes at 37°C, and washes for 10
minutes at 48°C in 1 3 SSC, 0.5 3 SSC and 0.25 3 SSC,
respectively.
Immunohistological detection of hybridized probes. After post-
hybridization washes, the sections were equilibrated in dig-buffer
I (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.5) and blocked by incubation
for one hour with 1% normal sheep serum. Alkaline phosphatase-
conjugated sheep anti-digoxigenin-Fab fragments (750 U/ml),
diluted 1:500 in dig-buffer containing 0.3% Triton X100 and 1%
normal sheep serum were applied to each slide and incubated
overnight at 4°C. Unbound conjugate was removed by two 10
minutes washes in dig-buffer I followed by equilibration of the
sections in dig-buffer II (100 mM Tris-HCl, 100 mM NaCl, 50 mM
MgCl2, pH 9.5). The detection of the signal was performed by
incubation at 4°C in darkness for up to 40 hours in a chromogen
solution containing 0.375 mg/ml nitro blue tetrazoliumchloride
(NBT) and 0.188 mg/ml 5-bromo-4-chloro-3-indolyl phosphate
(BCIP) in dig-buffer II. At optimal color development, the
reaction was halted by immersing the slides in 10 mM Tris-HCl, 1
mM EDTA, pH 8.0.
Subsequently, the slides were counterstained with neutral red
and visualized by light microscope.
Morphological investigations
Indices of renal damage (glomerular sclerosis, tubulointerstitial
and vascular damage). The total area of sclerosis within the
glomerular tuft as an index of progression was determined
adopting the semiquantitative scoring system proposed by El
Nahas et al [26]. Using light microscopy, a glomerular score was
derived for each animal by examining 100 glomerula at a magni-
fication of 3400. The severity of scarring was expressed on an
arbitrary scale from 0 to 4. The glomerular score for individual
glomerula was: grade 0, normal glomerula; grade 1, presence of
mesangial expansion/thickening of the basement membrane;
grade 2, mild/moderate segmental hyalinosis/sclerosis involving
less than 50% of the glomerular tuft; grade 3, diffuse glomerular
hyalinosis/sclerosis involving more than 50% of the tuft; grade 4,
diffuse glomerulosclerosis with total tuft obliteration and collapse.
The resulting index in each animal was expressed as a mean of all
scores obtained.
A tubulointerstitial score (0 to 4) and vascular changes (0 to 3)
was also used: tubulointerstitial (histological expressed in tubular
atrophy, dilation, casts, interstitial inflammation, and fibrosis) and
vascular changes were assessed using the semiquantitative scoring
system proposed by Ve´niant et al [27]. In PAS stained paraffin
sections at a magnification of 3100, ten fields per kidney were
randomly sampled and graded as follows: grade 0, no changes;
grade 1, lesions involving less than 25% of the area; grade 2,
lesions affecting 25 to 50%; grade 3, lesions involving more than
50% and grade 4 involving (almost) the entire area.
Glomerular geometry. Area (AA) and volume density (VV) of
the renal cortex and medulla as well as the number of glomeruli
per area (NA) were measured using a Zeiss eyepiece (Integrations-
platte II; Zeiss Co., Oberkochen, Germany) and the point count-
ing method (PP 5 AA 5 VV) at a magnification of 3400 [23, 24].
The number of glomeruli per area (NA) was then corrected for
tissue shrinkage (45%).
Total cortex volume (Vcortex) was derived from kidney mass
devided by specific weight of the kidney (1.04 g/cm3) times the
volume density of the cortex. Glomerular geometry was analyzed
as follows: Volume density (VV) of glomerula and area density of
glomerular tuft (AAT) were measured by point counting according
to PP 5 AA 5 VV [23, 24] at a magnification of 3400 on HE
sections.
Total area of glomerular tuft (AT) was then determined as
AT 5 AAT 3 Acortex
The number of glomerula per volume (NV) was then derived from
glomerular area density (NA) and the volume density (VV) of
glomerula using the formula:
NV 5 k/b 3 NA1.5/VV0.5
with k 5 1 and b 5 1.382.
The total number of glomeruli was derived from the total
volume of the renal cortex and the number of glomeruli per cortex
volume:
Nglom 5 NV 3 Vcortex
The mean glomerular tuft volume was determined according to
v 5 b/k 3 AT1.5
with b 5 1.382 and k 5 1 [23, 24].
Immunohistological investigations. The tissue sections stained
for PCNA positive cells were examined using light microscopy at
a magnification of 3400. Fifty glomeruli per kidney were selected
and the number of PCNA-positive cells were counted.
Statistics
Data are given as mean 6 SD. The Kruskal-Wallis test and
one-way ANOVA respectively were chosen for analysis of vari-
ance, followed by Ducan’s multiple-range test to determine
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whether or not the differences between the groups were signifi-
cant. The results were considered significant when the probability
of error (P) was less than 0.05.
RESULTS
Animal data
Table 1 lists the pertinent data in experiment 1 (8 weeks duration)
and experiment 2 (16 weeks).
It is of note that in the short-term study body weight was
significantly lower in 1,25(OH)2D3 treated animals; this was not
true for the long-term study. Because of the pair-feeding protocol,
food consumption was identical in the SNX 1 ethanol and sham
operated 1 ethanol-treated animals, that is, 234 6 32.4 g per eight
days, and in the SNX 1 1,25(OH)2D3 and sham operated 1
1,25(OH)2D3 treated animals, that is, 214 6 31.3 g per eight days.
Treatment with 1,25(OH)2D3 had no consistent effect on
systolic blood pressure (BP) at the end of the experiment, on left
ventricle (LV) weight or the LV/body wt ratio. Treatment with
1,25(OH)2D3 caused a modest increase of serum calcium within
the normal range.
In ethanol treated SNX rats the relative weight of the left
kidney remnant (4.54 6 0.55 g/g body wt 3 1023) was significantly
higher than the left kidney weight/body wt ratio of sham operated
controls (3.65 6 0.28 g/g body wt 3 1023). Treatment with
1,25(OH)2D3 had no significant effect [4.98 6 0.45 in SNX 1
1,25(OH)2D3 and 3.96 6 0.41 in sham operated 1 1,25(OH)2D3;
all data are from experiment 1].
Short-term study (experiment 1)
As shown in Table 2, SNX reduced the number of glomeruli by
approximately 70%. In untreated animals the mean glomerular
volume increased on average by a factor of 2. Total glomerular
volume (that is, conceptually the volume of all glomeruli per
kidney or kidney remnant combined) was only slightly decreased
as a result of a compensatory increase in the mean volume of
individual glomerula.
In ethanol treated SNX the glomerulosclerosis index was
significantly increased. In rats treated with 1,25(OH)2D3 the
glomerulosclerosis index was lower, both in sham operated and
SNX (Table 2 and Fig. 1).
Treatment with 1,25(OH)2D3 had no significant influence on
the vascular sclerosis index (SNX 1 ethanol 1.08 6 0.13; SNX 1
1,25(OH)2D3 1.19 6 0.14) or tubulointerstitial index (SNX 1
ethanol 1.30 6 0.22; SNX 1 1,25(OH)2D3 1.28 6 0.30).
The relative contribution of cortex and medulla in coronal
sections of the kidney remnant was normalized after eight weeks
(and 16 weeks; Table 3). A marginal effect was seen with
1,25(OH)2D3 treatment.
In a repeat eight week experiment comprised of subtotally
nephrectomized rats, a pair-feeding protocol was used (Table 4).
Ethanol and 1,25(OH)2D3 treated animals were compared. Body
weight in 1,25(OH)2D3 treated animals was again significantly
lower than in ethanol controls despite the identical food intake.
Serum calcium concentration and urinary calcium excretion were
only modestly increased. Plasma 1,25(OH)2D3 concentrations
documented adequate delivery of the secosterole by the osmotic
minipump. Albumin excretion rates were significantly higher in
ethanol compared to 1,25(OH)2D3 treated animals. With the
exception of one pair, there was no overlap of values.
Long-term study (experiment 2)
In the long-term experiment with a similar reduction of the
number of glomeruli, a more marked increase in mean glomerular
volume was noted (Table 2). The glomerulosclerosis index was
also higher in the ethanol treated animals compared to experi-
ment 1. Again, a significant reduction of the mean glomerular
volume and glomerulosclerosis index was seen in SNX treated
with 1,25(OH)2D3 (Table 2 and Fig. 1). As in experiment 1, no
Table 1. Animal data
Experiment 1 (8 weeks) Experiment 2 (16 weeks)
N
Body wt
g
Systolic
BPa
mm Hg
LV/body
wt ratio
[31023]
SCr SCa
N
Body wt
g
Systolic
BPa
mm Hg
LV/body
wt ratio
[31023]
SCr SCa
mg/dl mg/dl
Sham operated
1 ethanol
12 488 6 34.0c 116 6 11.3 1.88 6 0.11 0.65 6 0.88 2.45 6 0.34 10 467 6 23.0 114 6 8.67 2.34 6 0.29 0.91 6 0.10 2.28 6 0.14
Sham operated
1
1,25(OH)2D3
12 436 6 38.9 123 6 12.1 1.90 6 0.14 0.66 6 0.10 2.50 6 0.27 10 471 6 27.2 119 6 9.70 2.30 6 0.40 0.92 6 0.09 2.39 6 0.09
Subtotal
nephrectomy
1 ethanol
11 456 6 58.8d 122 6 12.7 2.49 6 0.37bc 0.95 6 0.07bc 2.58 6 0.14bc 12 487 6 33.7b 131 6 11.1bc 2.44 6 0.38 1.50 6 0.25bc 2.36 6 0.13
Subtotal
nephrectomy
1
1,25(OH)2D3
8 412 6 38.0b 129 6 25.7 2.43 6 0.31bc 0.89 6 0.10bc 2.67 6 0.20bc 13 465 6 22.4 130 6 18.6b 2.38 6 0.30 1.63 6 0.14bc 2.43 6 0.07
P, Analysis of
variance
, 0.05 NS , 0.05 , 0.05 , 0.05 , 0.05 , 0.05 NS , 0.05 NS
Abbreviations are: LV, weight of perfusion-fixed left ventricle; SCr, serum creatinine; SCa, serum calcium.
a At the end of the experiment
b P , 0.05 vs. sham operated rats treated with ethanol
c P , 0.05 vs. sham operated rats treated with 1,25(OH)2D3
d P , 0.05 vs. SNX rats treated with 1,25(OH)2D3
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significant effect of 1,25(OH)2D3 treatment was noted either on
vascular damage index or the interstitial damage index (data not
shown).
Ancillary studies
The number of PCNA positive cells in PTX rats examined seven
days after SNX was significantly lower with the 1,25(OH)2D3
treatment (Table 5). This was true for sham operated and for
SNX animals. A representative example of the effect of
1,25(OH)2D3 treatment in SNX 1 PTX rats is shown in Figure 2.
An in situ hybridization study to assess the expression of TGF-b
in parathyroid intact SNX rats without or with 1,25(OH)2D3
treatment, studied seven days after SNX, showed considerably
less expression of TGF-b mRNA in animals treated with
1,25(OH)2D3. This was particularly noticeable in the vascular wall
and in tubuloepithelial cells usually exhibiting the characteristics
of proximal tubular cells. A representative example is shown in
Figure 3. The expression in glomerular tissue was relatively low
seven days after SNX.
DISCUSSION
The above experiments were designed to test the working
hypothesis that 1,25(OH)2D3 interfered with (i) glomerular pro-
liferation and growth and (ii) development of glomerulosclerosis.
Fig. 1. Median and range of individual
glomerulosclerosis indices (A, 8 week
experiment; B, 16 week experiment).
Table 2. Glomerular measurements
Experiment 1 (8 weeks) Experiment 2 (16 weeks)
N
Glomerulo-
sclerosis index
Total
glomerular
volume [cm3]
per kidney
Total
number of
glomeruli
Mean
volume of
individual
glomerula
(3 106mm3) N
Glomerulo-
sclerosis index
Total
glomerular
volume [cm3]
per kidney
Total
number of
glomeruli
Mean
volume of
individual
glomeruli
(3106 mm3)
Sham operated
1 ethanol
12 0.41 6 0.08b 0.104 6 0.01 27511 6 3646 3.81 6 0.54 10 0.54 6 0.07 0.11 6 0.01 29094 6 3855 3.87 6 0.71
Sham operated 1
1,25(OH)2D3
12 0.23 6 0.08 0.102 6 0.02 33258 6 4584a 2.70 6 0.45 10 0.51 6 0.06 0.10 6 0.02 30976 6 5685 3.28 6 0.64
Subtotal
nephrectomy
1 ethanol
11 1.16 6 0.14abc 0.089 6 0.01ab 11985 6 1763ab 8.50 6 1.61ab 12 1.25 6 0.17abc 0.14 6 0.03abc 13840 6 3401ab 10.1 6 1.75ab
Subtotal
nephrectomy 1
1,25(OH)2D3
8 0.80 6 0.16ab 0.089 6 0.02ab 11608 6 1749ab 7.99 6 2.03ab 13 0.93 6 0.11ab 0.10 6 0.02 14179 6 2178ab 7.04 6 1.78abc
P, Analysis of
variance
, 0.01 , 0.05 , 0.05 , 0.05 , 0.001 , 0.05 , 0.05 , 0.05
a P , 0.05 vs. sham operated rats treated with ethanol
b P , 0.05 vs. sham operated rats treated with 1,25(OH)2D3
c P , 0.05 vs. SNX rats treated with 1,25(OH)2D3
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In order to avoid biostatistical artifacts from repetitive testing
(Bonferroni problem) mean glomerular volume and glomerulo-
sclerois index were predefined as the primary study endpoints.
Statistical analysis of the other parameters must be considered
exploratory in nature. We carried out two main experiments of 8
and 16 weeks duration, respectively, first to confirm the findings
and second to see whether the effect of 1,25(OH)2D3 is more
pronounced as times passes. The experiments showed that in
1,25(OH)2D3 treated subtotally nephrectomized rats (SNX) (i)
the mean glomerular volume tended to be less (the difference was
significant in the 8 week experiment) and (ii) the glomeruloscle-
rosis index was significantly lower. These findings are in agree-
ment with the working hypothesis that 1,25(OH)2D3 interferes
with glomerular growth and scarring. The in vivo relevance of this
finding is supported by a repeat experiment that showed that eight
weeks after SNX the urinary albumin excretion rate was signifi-
cantly lower in animals treated with 1,25(OH)2D3 compared to
pair-fed animals treated with ethanol. The working hypothesis was
further supported by ancillary experiments that documented less
proliferation of renal cells using the PCNA technique [28]. With
respect to the genesis of renal scarring, it is of interest that the
expression of the sclerosis-promoting cytokine TGF-b in tubular
cells and in the vascular wall was markedly less in SNX animals
treated with 1,25(OH)2D3 when evaluated by non-radioactive in
situ hybridization.
We emphasize that we examined a non-hypertensive model of
relatively modest renal damage. Further studies are required to
assess whether the results can be generalized, that is, whether they
can be extrapolated to hypertensive models and models of more
severe glomerulosclerosis.
The above significant effect of 1,25(OH)2D3 on glomerular
volume after 16 weeks is of interest because increased glomerular
volume is apparently a permissive factor for the genesis of
Table 3. Zonal analysis of kidney
Experiment 1 (8 weeks) Experiment 2 (16 weeks)
N Cortex % Medulla % N Cortex % Medulla %
Sham operated 1 ethanol 12 68.8 6 1.32 31.2 6 1.32 10 70.0 6 2.99 30.1 6 2.89
Sham operated 1
1,25(OH)2D3
12 68.5 6 3.46 31.5 6 3.46 10 70.8 6 3.58 29.2 6 3.62
Subtotal nephrectomy 1
ethanol
11 64.8 6 2.94abc 35.8 6 2.94ab 12 68.1 6 3.76 31.9 6 3.78
Subtotal nephrectomy 1
1,25(OH)2D3
8 69.4 6 3.48 30.6 6 3.48 13 70.1 6 4.35 30.0 6 4.40
P, Analysis of variance , 0.05 , 0.05 NS NS
a P , 0.05 vs. sham operated rats treated with ethanol
b P , 0.05 vs. sham operated rats treated with 1,25(OH)2D3
c P , 0.05 vs. SNX rats treated with 1,25(OH)2D3
Table 4. Calcium metabolism and albuminuria (8 week experiment)
N
Body
weight
g
SCr SCa
UCaV
mmol/24 hr
Serum-
1,25(OH)2D3
concentration
ng/ml
UAlV
mg/24 hrmg/dl
Subtotal nephrectomy
1 ethanol
10 396 6 17.2 1.02 6 0.15 2.68 6 0.07 149 6 50.9 22.3 6 9.04a 3.75b (1.29–14.2)
Subtotal nephrectomy
1 1,25(OH)2D3
9 365 6 26.1 0.76 6 0.08 2.71 6 0.08 216 6 59.7 69.0 6 18.4 0.785 (0.43–1.80)
Mann-Whitney U test
for pair differences, P
, 0.05 , 0.01 NS , 0.05 , 0.01 , 0.01
All data were collected at the end of the experiment (pair-feeding between animals with 1,25(OH)2D3 and ethanol, respectively). Abbreviations are:
SCr, serum creatinine; SCa, serum calcium; UCaV, urinary calcium excretion; UAlbV, urinary albumin excretion.
a At the beginning of the experiment, 43.1 6 10.3 ng/ml
b Given as median and range
Table 5. Number of PCNA positive cells in parathyroidectomized
(PTX) rats examined 7 days after subtotal nephrectomy or sham
operation, respectively
Number of PCNA positive cells
per
glomerulum
per mm2 of
tubulointerstitial space
Sham operated 1 PTX 1
ethanol (N 5 10)
3.74 6 1.99 17.5 6 8.49
Sham operated 1 PTX 1
1,25(OH)2D3 (N 5 10)
1.30 6 1.31a 8.18 6 5.17
SNX 1 PTX 1 ethanol
(N 5 9)
4.90 6 2.15b 66.1 6 23.0abc
SNX 1 PTX 1
1,25(OH)2D3 (N 5 9)
3.38 6 1.61b 26.5 6 12.3b
P, Analysis of variance , 0.05 , 0.05
a P , 0.05 versus parathyroidectomized sham operated rats treated with
ethanol
b P , 0.05 versus parathyroidectomized sham operated rats treated with
1,25(OH)2D3
c P , 0.05 versus parathyroidectomized subtotally nephrectomized rats
treated with 1,25(OH)2D3
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glomerulosclerosis. This is illustrated by the experiment of Yo-
shida, Fogo and Ichikawa [19], who found glomerulosclerosis only
when renal damage was associated with glomerulomegaly. Stim-
ulation of glomerular growth also apparently contributes to the
development of glomerulosclerosis in transgenic animals express-
ing bovine growth hormone [29]. The mechanism through which
increased glomerular volume promotes glomerulosclerosis has
not been finally settled. One plausible hypothesis postulates that
when glomerular volume increases the domains controlled by
individual podocytes increase in parallel [30]. Since podocytes are
postmitotic cells, their number cannot increase. Expansion of the
filtering surface domain is thought to strain the capacity of
podocytes to compensate or adapt, thus leading to local areas of
podocyte malfunction [30–33]. An alternative or complementary
idea is that capillary wall stress must increase with increasing
glomerular volume and capillary diameter [34].
Fig. 2. PCNA staining in tubules of parathyreoidectomized (PTX), subtotally nephrectomized rats. Comparison of animal without (A) and with (B)
1,25(OH)2D3 treatment (magnification 3100).
Fig. 3. Expression of transforming growth factor-B (TGF-b), as assessed
by in situ hybridization, in afferent arteries of subtotally nephrectomized
rats (SNX). Comparison of SNX without (A) and with (B) 1,25(OH)2D3
treatment (A and B), TGF-b sense (C), antisense control to B (antisense
control to A not shown) (magnification 351).
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When designing the above study we tried to avoid several
known confounding factors. First, the uremic milieu may intro-
duce confounding variables, such as metabolic acidosis, severe
hyperphosphatemia, severe hyperparathyroidism, etc. In order to
circumvent such problems, we intentionally induced only a mod-
erate reduction of the number of glomeruli so that the animals
were not severely uremic. Second, elevated blood pressure is of
overriding importance for the development of glomerular injury
[35]. Consequently, blood pressure was monitored (and as an
ancillary indicator of blood pressure-induced target organ damage
we also assessed left ventricular weight). Both indicators showed
that the animals were not severely hypertensive and also docu-
mented that 1,25(OH)2D3 had no significant effect on blood
pressure. Another variable is the type of subtotal nephrectomy.
Vascular ligation causes more marked hyperreninism [36] than
surgical resection as adopted in the present study [37]. This point
is of interest in view of the known effect of an activated renin
system on the development of glomerulosclerosis.
In the 1,25(OH)2D3 treated SNX body wt was significantly
lower than in ethanol treated SNX in the eight weeks experiment.
A significant difference was no longer seen 16 weeks after SNX.
Food consumption had not been significantly different, but to
further exclude any artifact of food intake we carried out a repeat
eight week experiment (Table 4) in which 1,25(OH)2D3 treated
SNX were pair-fed with ethanol treated SNX. Despite an identical
food intake the final body wt was significantly lower in
1,25(OH)2D3 treated animals. Despite no difference in food
intake, albuminuria was significantly greater in the ethanol treated
SNX. Consequently, we can safely exclude an artifact resulting
from lower intake of protein, sodium or phosphate. We cannot
definitely exclude the possibility that body wt per se influences
development of glomerulosclerosis independent of food intake as
described elsewhere [38]. Whether lower body wt in 1,25(OH)2D3
treated animals points to increased metabolism, diminished anab-
olism, or fluid loss cannot be decided on the basis of these
findings.
Based on a pilot experiment and previous studies in this
laboratory [39] a dose of 1,25(OH)2D3 was selected that did not
cause hypercalcemia. Nevertheless, some increases of serum
calcium and urinary calicum excretion were seen. We intentionally
used delivery by osmotic minipumps, since previous studies had
shown that the effect of 1,25(OH)2D3 depends on the concentra-
tion time profile, that is, intermittent versus continuous adminis-
tration [39]. The dose administered was in the range of estimated
daily endogenous synthesis of 1,25(OH)2D3 [40]. The achieved
concentration of 1,25(OH)2D3 were not in the frankly pharmaco-
logical range.
While in the above study significantly less glomerulosclerosis
was documented in animals treated with 1,25(OH)2D3, no signif-
icant effect was seen with respect to tubulointerstitial or vascular
damage. This negative finding is presumably the result of the very
modest degree of renal damage. The vascular and tubulointersti-
tal lesions were so minor that the method may not have been
sensitive enough to detect an effect of 1,25(OH)2D3. To confirm
or refute this hypothesis rats with more advanced renal failure
must be examined.
The kidney is known to have vitamin D receptors (VDR),
particularly in tubular epithelial cells [16], and also in glomerular
cells [15]. It is conceivable that the effect of 1,25(OH)2D3 is
mediated via direct interaction with the vitamin D receptor. To
exclude an alternative possibility, that is, that the effect seen with
1,25(OH)2D3 was due to suppression of PTH secretion, we
compared cell proliferation, as evaluated by PCNA technique, in
parathyroidectomized SNX animals treated with ethanol or
1,25(OH)2D3, respectively. In animals treated with 1,25(OH)2D3
the number of PCNA positive cells, predominantly in the tubulo-
interstitial space, was significantly less. This finding excludes an
artifact from changes in PTH concentration, but it does not
provide information whether the effect of 1,25(OH)2D3 is medi-
ated via genomic or non-genomic effects of the secosterole.
Whether responsiveness to 1,25(OH)2D3 is altered secondary to
defective interaction with the retinoic acid receptor (RXR), as
suggested by the experiments of Sawaya et al [41] was not
explored in this study.
The outcome of the present study extends previous in vivo [14]
and in vitro [15, 16] studies and shows that an inhibitory effect of
1,25(OH)2D3 on renal cell proliferation can also be seen in the
ablation model of renal damage. Whether suppressed cell prolif-
eration and attenuation of glomerular enlargement are the only
explanations for this finding is uncertain. Involvement of T-cells
and macrophages in the genesis of progression has been docu-
mented in numerous studies. In this context, it is of interest that
1,25(OH)2D3 [42] and vitamin D analogs [43] prevent renal injury
in immune models of renal damage, that is, active Heyman
nephritis and mercury-chloride-induced autoimmune glomerulo-
nephritis of the Brown Norway rat. Diminished recruitment of T
and B cells, inhibition of the synthesis of various interleukins (IL),
especially IL-2 [44, 45] and IL-6 [46], defective antigen presenta-
tion by lowering expression of MHC-II molecules [47, 48] and
other mechanisms have been proposed, but not definitely proven.
Nevertheless, it is of interest that active vitamin D metabolites
also have been shown to interfere with autoimmune damage in
non-renal models, such as diabetes mellitus [49], encephalitis [50]
and non-renal allograft survival [51].
The results of our study suggest that development of renal
fibrosis, at least glomerular fibrosis, is attenuated by
1,25(OH)2D3. In other cell systems 1,25(OH)2D3 has been shown
to stimulate synthesis of fibronectin [52], and a recent preslimi-
nary short term in vitro study using mice proximal tubular cells
found stimulation of TGF-b1 [53]. This study is not necessarily in
conflict with our observation, since in models of renal injury the
effect of TGF-b varies with time; notably, TGF-b has antiprolif-
erative effects (which may predominate in a early phase) and
pro-fibrotic effects (which may predominate in a later phase) [54].
It is conceivable that the effect of 1,25(OH)2D3 on TGF-b is time
dependent, and this possibility requires further study.
What are the implications of the above findings?
Since the dose of 1,25(OH)2D3 administered was not in the
pharmacological range, it is conceivable that reduced renal syn-
thesis of the secosterole 1,25(OH)2D3 and lower concentrations of
endogenous 1,25(OH)2D3 play a role in the genesis of glomeru-
losclerosis and possibly progression of renal failure. This idea
becomes even more attractive since the concentrations in the
vinicity of the proximal tubular cell, the site of endogenous
synthesis of 1,25(OH)2D3, may be considerably higher than in the
systemic circulation [16]. Further experiments are necessary to
confirm or refute this hypothesis.
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Does the above observation have potential clinical
implications?
In the past the concern about potentially nephrotoxic effects of
1,25(OH)2D3 [2] had already been allayed by the results of
controlled clinical studies [3–7], which failed to show accelerated
progression in patients on treatment with active vitamin D. Such
concerns are thoroughly dispelled by the present experimental
study, which even documents a beneficial effect of 1,25(OH)2D3
on glomerular injury. Though significant, the effect is modest in
magnitude and would not justify administration of 1,25(OH)2D3
with the aim of reducing progression, even if the above animal
data could be extrapolated to human beings. At the very least,
however, changes in 1,25(OH)2D3 concentration must be consid-
ered as a potential confounder in future experiments on progres-
sion. Furthermore, administration of 1,25(OH)2D3 provides an
interesting experimental tool to modulate progression.
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